J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 35,232 Cr.
- Current Price ₹ 2,193
- High / Low ₹ 2,225 / 1,603
- Stock P/E 48.3
- Book Value ₹ 259
- Dividend Yield 0.71 %
- ROCE 25.8 %
- ROE 19.2 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 30.7%
- Promoter holding has increased by 1.25% over last quarter.
Cons
- Stock is trading at 8.46 times its book value
- Promoter holding has decreased over last 3 years: -5.13%
- Working capital days have increased from 108 days to 191 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty500 Shariah
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,918 | 4,148 | |
| 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,587 | 2,886 | 3,040 | |
| Operating Profit | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 1,032 | 1,107 |
| OPM % | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 26% | 26% | 27% |
| 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 38 | 33 | |
| Interest | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 12 | 6 |
| Depreciation | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 171 | 182 |
| Profit before tax | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 952 |
| Tax % | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | 26% | 26% | 26% |
| 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 709 | |
| EPS in Rs | 5.92 | 9.58 | 10.85 | 8.28 | 12.05 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 42.37 | 44.19 |
| Dividend Payout % | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% | 34% | 37% | 21% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 10% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 13% |
| 3 Years: | 22% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| 1 Year: | 30% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 19% |
| 3 Years: | 20% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
| Reserves | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 | 3,418 | 4,143 |
| 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 378 | 28 | 2 | |
| 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 687 | 804 | 807 | |
| Total Liabilities | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,969 |
| 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 | 1,968 | 1,898 | |
| CWIP | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 63 | 61 |
| Investments | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 | 765 |
| 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,385 | 1,519 | 1,889 | 2,244 | |
| Total Assets | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,265 | 4,969 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 | 902 | 704 | |
| -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 | -296 | -586 | |
| -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -385 | -580 | -123 | |
| Net Cash Flow | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 | 27 | -5 |
| Free Cash Flow | 56 | -63 | 48 | 94 | 153 | 205 | 315 | -529 | -138 | 540 | 783 | 623 |
| CFO/OP | 91% | 94% | 107% | 75% | 85% | 97% | 81% | 56% | 104% | 104% | 107% | 87% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 | 72 | 76 | 69 |
| Inventory Days | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 134 | 155 | 147 | 192 |
| Days Payable | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 | 110 | 114 | 110 |
| Cash Conversion Cycle | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 | 117 | 109 | 151 |
| Working Capital Days | 16 | 38 | 75 | 93 | 91 | 81 | 91 | 122 | 81 | 55 | 79 | 191 |
| ROCE % | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 22% | 25% | 26% | 26% |
Insights
In beta| Mar 2011 | Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical Representative Productivity (PCPM) INR Lakhs per month ・Standalone data |
|
|||||||||
| Number of Brands in Top 300 (IPM) Count ・Standalone data |
||||||||||
| Field Force Strength (Medical Representatives) Count ・Standalone data |
||||||||||
| Cardiac Therapy Market Rank (IPM) Rank ・Standalone data |
||||||||||
| India Distribution Locations Count ・Standalone data |
||||||||||
| Lozenge Manufacturing Global Rank Rank |
||||||||||
| Annual New Product Launches (Domestic) Count ・Standalone data |
||||||||||
| Domestic Formulations Volume Growth % ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1h - Secretarial compliance report for FY2025-26 issued; company reported full compliance with SEBI regulations.
-
Intimation Of Record Date
1d - May 29, 2026 set as record date for FY2025-26 final dividend eligibility.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 2d
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 May - Q4 FY26 call: revenue INR904 crore, PAT INR101 crore, final dividend INR9.3, merger hearing in June.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 May - Q4FY26 results and developments investor call recording available on company website.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
May 2026TranscriptPPT
-
Jan 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
Jun 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Dec 2023Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Sep 2019TranscriptAI SummaryPPT
Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]